🇺🇸 FDA
Patent

US 11285210

Buffer formulations for enhanced antibody stability

granted A61KA61K2039/54A61K39/39591

Quick answer

US patent 11285210 (Buffer formulations for enhanced antibody stability) held by Outlook Therapeutics, Inc. expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Outlook Therapeutics, Inc.
Grant date
Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/54, A61K39/39591, A61K47/12, A61K47/183